Alterity Therapeutics (ASX:ATH)
ASX announcement history & article coverage
Transparent by design.
Announcments by Alterity Therapeutics (ASX:ATH) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
ATH Receives A$3.98m R&D Tax Incentive
Alterity Therapeutics Receives A$3.98m R&D Tax Incentive Refund
Application for quotation of securities - ATH
FDA Meeting Minutes Confirm Registrational Path for ATH434
FDA Confirms Registrational Pathway for Alterity's ATH434 in Multiple System Atrophy
Application for quotation of securities - ATH
Change in substantial holding
Change of Director's Interest Notice x 2
Corporate Presentation June 2026
Notification regarding unquoted securities - ATH
Notification of cessation of securities - ATH
Completion of Consolidation
Alterity and FDA Agree on Phase 3 Program for ATH434 in MSA
Alterity Therapeutics Secures FDA Alignment on Phase 3 Trial Design for ATH434 in Multiple System Atrophy
Share Consolidation Effective, Trading Under ATHDA
Change of Registered Office Address
Results of Meeting
Alterity Data Supports ATH434 Phase 3 Advancement in MSA
Alterity Therapeutics Advances ATH434 to Phase 3 for Multiple System Atrophy Following Positive Phase 2 Data
Corporate Presentation May 2026
Alterity Announces Publication on MRI as Biomarker for MSA
Alterity to Deliver Presentations at May Medical Meetings
Consolidation/Split - ATH
Quarterly Activities/Appendix 4C Cash Flow Report
Alterity Therapeutics advances ATH434 Phase 3 plans with FDA alignment and strong clinical data, holds A$44.53M cash
Notice of General Meeting/Proxy Form
Alterity Therapeutics calls virtual AGM on 29 May 2026 for director elections, capital consolidation, and option issuances
Alterity Receives Positive FDA Feedback on CMC Meeting
Alterity Therapeutics Secures Positive FDA Feedback on ATH434 Phase 3 Program for MSA
Change in substantial holding
Alterity Presents New Analysis of ATH434 Phase 2 Data at AAN
Alterity Therapeutics Reports Positive Phase 2 Data for ATH434 in Multiple System Atrophy
Initial Director's Interest Notice - Cunningham
Notification regarding unquoted securities - ATH
Notification regarding unquoted securities - ATH
Alterity Appoints Biotech Executive Ann Cunningham to Board
Alterity Announces Late-Breaker Oral Presentation at AAN
Alterity to Host KOL Event to Share New Insights on ATH434